The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties

by Nakai, Kiyohiko, Tobinai, Masato, Hashimoto, Junko, Iida, Satofumi, Kawanishi, Takehiko
Published 2014

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis

by Nakamura, Toshitaka, Nakano, Tetsuo, Ito, Masako, Hagino, Hiroshi, Hashimoto, Junko, Tobinai, Masato, Mizunuma, Hideki
Published 2013

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER S...

by Hagino, Hiroshi, Yoshida, Seitaro, Hashimoto, Junko, Matsunaga, Masayuki, Tobinai, Masato, Nakamura, Toshitaka
Published 2014

Biosynthesis of Versipelostatin: Identification of an Enzyme-Catalyzed [4+2]-Cycloaddition Required for Macrocyclization of Spirotetronate-Containing Polyketides

by Hashimoto, Takuya, Hashimoto, Junko, Teruya, Kuniko, Hirano, Takashi, Shin-ya, Kazuo, Ikeda, Haruo, Liu, Hung-wen, Nishiyama, Makoto, Kuzuyama, Tomohisa
Published 2014